By S. Bernal
This well timed new reference integrates the most recent medical effects and laboratory stories at the resistance of particular cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon melanoma in addition to hematological malignancies.
Read or Download Drug Resistance in Oncology (Basic and Clinical Oncology) PDF
Best clinical medicine books
Cognitive Behaviour treatment is extensively altering the best way humans deal with difficulties of their lives and has a profoundly optimistic influence on activity delight for psychological medical experts. The Case examine consultant to Cognitive Behaviour treatment of Psychosis is written by way of practitioners from differing scientific backgrounds and at varied phases of their use of CBT.
It has lengthy been recognized that features of habit run in households; reviews convey that features with regards to cognition, temperament, and all significant psychiatric problems are heritable. This quantity bargains a primer on realizing the genetic mechanisms of such inherited features. It proposes a suite of tools—a conceptual basis—for significantly comparing contemporary reviews and provides a survey of effects from the most recent learn within the rising fields of cognitive genetics and imaging genetics.
Written and edited via world-renowned leaders within the box! offers new instructions for the prevention and therapy of arterial and venous cardiovascular thrombotic and thromboembolic illnesses. Updates modern pondering relating to low-molecular-weight-heparins (LMWH), platelet receptor antagonists, and direct thrombin inhibitors to control acute coronary syndromes.
Whilst is hypnosis introduced into play with a variety of theoretical and medical methods to psychotherapy? What does a hypnotherapist really do on a case-by-case and a session-by-session foundation? What particular innovations will be carried out? What are the scope and nature of the demanding situations that hypnotherapists and their consumers face?
- A Clinician's Guide to Pulmonary Arterial Hypertension: Pocketbook, 2nd edition
- MedSurg Notes: Nurse's Clinical Pocket Guide
- Mayo Clinic Guide to a Healthy Pregnancy Collins
- Essential Clinical Anatomy, 4th Edition
- UCV BASIC SCIENCE COLOR ATLAS
- Pediatric Traumatic Brain Injury: New Frontiers in Clinical and Translational Research
Additional resources for Drug Resistance in Oncology (Basic and Clinical Oncology)
J Clin Oncol 1986; 4982986. 97. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase I1 trial in untreated patients. Clin Oncol 1986; 4524-527. 98. Woods RL, FOXRM, Tattersall MHN. Treatment of small d l bronchogenic carcinoma with W-26. Cancer Treat Rep 1979; 63:2011-2013. 99. Creech RH, Tritchler D, Ettinger DS, et al. Phase11study &A ' LA, amsacrim, teniposide, and zinostatinin small cell lung carcinoma (EST 2579).
Moreover, the specific protein kinases responsible for the in vivo phosphorylation of P-glycoprotein havenot been unequivocally identified. However, recent transfection-basedstudies have provided more direct evidence that phosphorylationby protein kinase isoform Ca (186,187), but not isoform (188), may be involved in augmenting P-glycoprotein-mediated drug resistance. P-glycoprotein may also be regulated by other kinases that have been studied to a lesser degree (189). Thus it has been suggested that the linker region may be a regulatory domain of P-glycoprotein function (190,191), analogous to theregulatory (“R”) domain in CFTR (37,192-194).
This Page Intentionally Left Blank 2 Shelagh E. L. Mirski and Susan C. Cole Queen'S Universiy, Kingston, Ontario, Canada INTRODUCTION The refinement of combination chemotherapy over the past two decades has significantly increased the median survivaltime of patientswith small celllung cancer (SCLC) (1). However, acquired resistance to multiple drugs is a major obstacle to successful treatment, anddespite improvements in survival, chemotherapy is responsible for the cure of less than 10% of patients.